These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32142185)

  • 1. Engineering a human IgG2 antibody stable at low pH.
    Saito S; Namisaki H; Hiraishi K; Takahashi N; Iida S
    Protein Sci; 2020 May; 29(5):1186-1195. PubMed ID: 32142185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress.
    Saito S; Namisaki H; Hiraishi K; Takahashi N; Iida S
    Protein Sci; 2019 May; 28(5):900-909. PubMed ID: 30834577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition.
    Hari SB; Lau H; Razinkov VI; Chen S; Latypov RF
    Biochemistry; 2010 Nov; 49(43):9328-38. PubMed ID: 20843079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates.
    Franey H; Brych SR; Kolvenbach CG; Rajan RS
    Protein Sci; 2010 Sep; 19(9):1601-15. PubMed ID: 20556807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a secondary Fc gamma RI binding site within a genetically engineered human IgG antibody.
    Chappel MS; Isenman DE; Oomen R; Xu YY; Klein MH
    J Biol Chem; 1993 Nov; 268(33):25124-31. PubMed ID: 8227075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acid-induced aggregation propensity of nivolumab is dependent on the Fc.
    Liu B; Guo H; Xu J; Qin T; Xu L; Zhang J; Guo Q; Zhang D; Qian W; Li B; Dai J; Hou S; Guo Y; Wang H
    MAbs; 2016; 8(6):1107-17. PubMed ID: 27310175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational implications of an inversed pH-dependent antibody aggregation.
    Perico N; Purtell J; Dillon TM; Ricci MS
    J Pharm Sci; 2009 Sep; 98(9):3031-42. PubMed ID: 18803243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc.
    Latypov RF; Hogan S; Lau H; Gadgil H; Liu D
    J Biol Chem; 2012 Jan; 287(2):1381-96. PubMed ID: 22084250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies.
    Ishikawa T; Ito T; Endo R; Nakagawa K; Sawa E; Wakamatsu K
    Biol Pharm Bull; 2010; 33(8):1413-7. PubMed ID: 20686240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
    Deveuve Q; Lajoie L; Barrault B; Thibault G
    Front Immunol; 2020; 11():168. PubMed ID: 32117299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R409K mutation prevents acid-induced aggregation of human IgG4.
    Namisaki H; Saito S; Hiraishi K; Haba T; Tanaka Y; Yoshida H; Iida S; Takahashi N
    PLoS One; 2020; 15(3):e0229027. PubMed ID: 32182240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays.
    Navas A; Molina J; Agüera ML; Guler I; Jurado A; Rodríguez-Benot A; Alonso C; Solana R
    Front Immunol; 2019; 10():1712. PubMed ID: 31428086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
    Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
    MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of weak/non-complement-binding HLA antibodies on C1q-binding.
    Hönger G; Amico P; Arnold ML; Spriewald BM; Schaub S
    HLA; 2017 Aug; 90(2):88-94. PubMed ID: 28585289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.
    Arosio P; Rima S; Morbidelli M
    Pharm Res; 2013 Mar; 30(3):641-54. PubMed ID: 23054090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.
    Canfield SM; Morrison SL
    J Exp Med; 1991 Jun; 173(6):1483-91. PubMed ID: 1827828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the chromatographic properties of IgG1 and IgG2 antibody subclasses.
    Ghose S; Ladwig J; Allen M
    Biotechnol Appl Biochem; 2010 Dec; 57(3):111-6. PubMed ID: 20874708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Destabilization of CH2 domains in intact IgG2 is accompanied by reduced ability to inhibit complement system factor C1.
    Timchenko MA; Tischenko VM
    Biochemistry (Mosc); 2013 Jun; 78(6):667-73. PubMed ID: 23980893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abolition of aggregation of CH
    Oyama K; Ohkuri T; Ochi J; Caaveiro JMM; Ueda T
    Biochem Biophys Res Commun; 2021 Jun; 558():114-119. PubMed ID: 33915325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.